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ABSTRACT 
Cytotoxic T lymphocytes (CTLs) specific for con- 
served viral antigens can respond to different strains 
of virus, in contrast to antibodies, which are generally 
strain-specific. The generation of such CTLs in vivo 
usually requires endogenous expression of the antigen, 
as occurs in the case of virus infection. To generate a 
viral antigen for presentation to the immune system 
without the limitations of direct peptide delivery or 
viral vectors, plasmid DNA encoding influenza A nu- 
cleoprotein was injected into the quadriceps of BALB/c 
mice. This resulted in the generation of nucleoprotein- 
specific CTLs and protection from a subsequent chal- 
lenge with a heterologous strain of influenza A virus, as 
measured by decreased viral lung titers, inhibition of 
mass loss, and increased survival. 
COMMENTS 
This work presents two novel concepts. The first is the 
use of naked plasmid DNA in gene therapy rather than 
DNA packaged into some more sophisticated complex 
such as a virus or lipid. The second is an effective vaccine 
that activates cell-mediated immunity rather than hu- 
moral immunity. 
The goal in gene-transfer research has been to get the 
gene you would like into a sufficient number of cells and 
have the desired protein expressed in sufficient quantity 
to  have a desired therapeutic benefit. Strategies for this 
have included packaging the gene in retroviral vectors, 
in adenoviral vectors and in cationically charged lipids 
(liposomes) called Lipofectin (1). Another level of com- 
plexity is encountered in targeting the vector to the 
desired tissue. Vectors can be given directly to  the 
animal tissues intravenously; intraarterially; as an 
aerosol; or through potential receptor ligands such as 
lysine-bound asialoglycosides, which are taken up by the 
liver by way of the asialoglycoprotein receptor. Alterna- 
tively, target cells (e.g., lymphocytes, hepatocytes, tumor 
cells) can be removed, transfected with the vector ex uiuo 
and then returned to the animal. But Jon Wolff at  the 
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University of Wisconsin and investigators from Vical, 
Inc. (San Diego, CAI, happened upon a much more direct 
mode of gene transfer (2). These investigators found 
that naked DNA in the form of a plasmid expression 
vector could be simply injected into animal muscle and 
the DNA would be taken up by the cells and expressed. 
They discovered this quite by accident when Wolff et al. 
used plasmid DNA with a reporter gene as a negative 
control in their gene-transfer experiments (3). Much to 
their surprise, they found that muscles injected with the 
negative control not only took up the DNA but also 
expressed high levels of the reporter protein. The next 
step was to devise some model in which this technology 
could be used to not express just a reporter gene but 
some gene that would potentially be of benefit to the 
animal and then actually demonstrate that benefit. 
Ulmer and colleagues accomplished this by using an 
influenza gene to induce immunity and protect recipient 
mice from a lethal dose of influenza A. 
To understand why gene-transfer technology was 
essential in the study under comment to induce im- 
munity against influenza, a word on antigen processing 
is in order. Antigen processing and, therefore, the 
immune response to vaccines are generally divided into 
two systems, although considerable crossover exists (4). 
The first is the class I1 major histocompatibility complex 
(MHC) system or the exogenous pathway. Here antigens 
that invade the body are taken up by phagocytosis or 
endocytosis into cells that express MHC class I1 mole- 
cules, such as macrophages or neutrophils. The antigen 
is processed in the endosome, where it binds the MHC 
molecule. MHC molecules are similar to antibodies in 
that they recognize distinct epitopes, but whereas 
antibody recognition is dependent in part on the sec- 
ondary and tertiary structure of the antigen, MHC 
molecules recognize processed antigens that are cleaved 
by proteosomes into oligopeptides of 8 to 12 amino acids. 
This complex is then transported to the cell surface, 
where it binds MHC class 11-restricted cluster of 
differentiation (CD4)(CD) 4-positive helper T cells, 
which then activate B cells and the humoral response. 
This is the mechanism by which most human vaccines 
induce immunity. This system cannot “see” inside cells, 
so antigens such as viral nucleoproteins that are 
produced intracellularly are not detected. The class I 
MHC system or the endogenous pathway is designed to 
identify intracellular antigens. All nucleated cells in the 
body express class I MHC molecules, which are located 
on the endoplasmic reticulum (ER). Intracellular an- 
tigens cleaved to 8- to 12-amino-acid peptides are then 
transported into the ER, where they bind to MHC class 
I molecules. The MHC-antigen complex then travels 
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through the Golg apparatus and is expressed on the cell 
surface. This complex is recognized by class I MHC 
CD8-positive restricted cytotoxic T lymphocytes, which 
in turn are activated and attack infected cells (Fig. 1). 
Influenza A is infamous for its ever-changing envelope 
proteins. If one has been vaccinated against a particular 
strain, when the virus first enters the body neutralizing 
antibodies against the envelope will prevent intracel- 
lular infection and reproduction of the virus. Next year, 
when the virus returns, the envelope proteins will have 
changed and the antibodies from last year’s vaccine no 
longer recognize the envelope’s antigenic epitopes. In- 
fluenza A nucleoprotein does not change significantly 
from year to year, which may indicate that the virus 
cannot survive major changes in nucleoprotein stucture. 
If one were to try to utilize the nucleoprotein as a vaccine 
by means of traditional methods, the induced class I1 
MHC humoral antibody response might not be effective 
against infection because antibody would not have 
access to the nucleoprotein in intact virions or cells. But 
if DNA coded for the nucleoprotein were used, the 
protein would be made intracellularly and processed 
through the endogenous pathway, and CD8-positive 
cytotoxic T lymphocytes (CTLs) could attack and clear 
cells containing the virion (Fig. 1). Ulmer and colleagues 
placed the DNA sequence for influenza nucleoprotein in 
a plasmid, a circular piece of bacterial DNA. In front of 
the nucleoprotein sequence they placed a Rous sarcoma 
virus promoter (i.e., a DNA sequence that would tell the 
host cell to transcribe the nucleoprotein DNA sequence 
into messenger RNA). From there the host cells would, 
with luck, translate the messenger RNA into protein. 
When Ulmer et al. actually gave the plasmid vector to 
mice by injecting it into the quadriceps muscle, they 
were able to show that mice developed antibodies and 
cytotoxic T lymphocytes to the nucleoprotein. Next they 
demonstrated that mice immunized with the vector 
could survive what would otherwise be a lethal dose of 
influenza A. This protection existed across different 
strains of influenza with different envelope proteins, 
something that would not occur with the usual influenza 
vaccines. The only difficulty with this work is that these 
investigators did not definitively demonstrate that CD8- 
positive restricted CTLs were the mechanism for the 
observed protection against influenza infection. As 
indirect evidence for the primary role of CTLs, Ulmer et 
al. immunized mice with purified nucleoprotein; these 
mice exhibited high titers of nucleoprotein IgG antibody 
but could not survive a lethal dose of virus. This 
indicates that humoral antibodies were insufficient to 
protect the animals; therefore cell-mediated CTLs were 
probably responsible for the observed protection against 
viral infection. 
These experiments may have important implications 
for developing a vaccine against hepatitis C virus (HCV). 
Some aspects of HCV infection, compared with those of 
HBV, suggest that traditional vaccine approaches may 
not be effective in inducing immunity against HCV (5). 
About 95% of persons who become infected with HBV 







FIG. 1. The plasmid vector containing an RSV promoter and 
influenza A nucleoprotein gene is injected into muscle and taken up by 
cells. The nucleoprotein gene is transcribed into messenger RNA, 
which is translated into nucleoprotein. The protein is cleaved, enters 
the endoplasmic reticulum and binds to MHC class I molecules, which 
are then transported through the Golgi apparatus to the cell surface, 
where the complex activates CTLs. 
virus. HBs antibody is considered neutralizing for HBV. 
Purified HBsAg is an effective vaccine against HBV- 
that is, the generation of HBs antibody is protective 
against infection. In HCV the story is quite different. 
More than 60% of persons infected with HCV become 
chronic carriers (6,7).  For whatever reason, most people 
cannot generate an  adequate immune response to clear 
the virus, and most will be subject to some form of liver 
damage. Antibodies generated against the nucleocapsid 
core region, NS3 and NS4 of the HCV genome, are pres- 
ent in most people chronically infected with HCV; there- 
fore these antibodies are not neutralizing (8, 9). HCV 
virus is detectable in most people who display these an- 
tibodies, and experiments in chimpanzees have shown 
that chimps can be reinfected with the same strain of 
HCV despite the presence of antibodies (10, 11). These 
data suggest that a humorally mediated vaccine may not 
protect against HCV infection. Chiron Corp. (Emery- 
ville, CAI, in conjunction with Ciba-Geigy (Basel, Swit- 
zerland) is developing a recombinant vaccine using HCV 
envelope glycoproteins and an undefined adjuvant. 
Their approach is a variation on traditional methodol- 
ogies to evoke a humoral response to an antigen. Prelim- 
inary data were presented in May at  the Triennial Inter- 
national Symposium on Viral Hepatitis and Liver Dis- 
ease in Tokyo by Michael Houghton Ph.D. Of seven 
chimpanzees given the vaccine and then challenged with 
HCV, five were judged to have remained infection-free 
on the basis of numerous parameters, including poly- 
merase chain reaction. All control animals in the exper- 
iment became infected. Although these preliminary data 
are encouraging, proven efficacy in human subjects is a 
ways off, and theoretical concerns remain. The approach 
outlined by Ulmer et al. may prove to be a useful alter- 
native for developing a vaccine to HCV if a traditional 
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vaccine does not work or as adjuvant therapy in persons 
already infected with HCV to augment the immune re- 
sponse and promote clearance of the virus. 
In closing, it should be noted that although current 
vaccines for H N  consist of recombinant gp 160 glyco- 
protein, Graham et al. are developing a human immu- 
nodeficiency virus vaccine using methods similar to 
those described here by inserting the gp 160 gene into 
vaccinia virus (HIVAC-le; Bristol-Meyers Squibb, Se- 
attle, WA) (12). HIVAC-le is given subcutaneously; it 
promotes a local vaccinia infection similar to that raised 
by the smallpox vaccine. In human trials this vaccine has 
generated both humoral and cell-mediated immune 
responses to gp 160. These investigators are now 
studying a combined approach using HIVAC-le virus 
followed by injections of recombinant gp 160 protein to 
produce a greater immunogenic response (13). This 
combined application is another approach that may lend 
itself to the prophylaxis or treatment of HCV. 
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ABSTRACT 
272-277. 
Essential mixed cryoglobulinemia is frequently as- 
sociated with chronic hepatitis. This report presents 
four cases of cryoglobulinemia with vasculitis asso- 
ciated with chronic hepatitis related to hepatitis C 
virus infection. Hepatitis C virus infection was ascer- 
tained in the four patients by both the presence in the 
serum of anti-HCV antibodies detected by the four- 
antigen recombinant immunoblot assay and of HCV 
RNA detected by polymerase chain reaction. In two 
patients tested, anti-HCV antibodies were not detected 
after centrifugation in the purified cryoglobulin but 
were detected in the supernatant. HCV RNA was 
detected in the purified cryoglobulin in all four pa- 
tients and was detected in the supernatant in three 
patients. In one patient receiving recombinant inter- 
feron alfa, serum aminotransferases normalized and 
cryoglobulin disappeared; in another patient receiving 
recombinant interferon alfa, serum aminotransferases 
remained high and the cryoglobulin persisted. The 
presence of HCV RNA in the cryoglobulin and the 
parallelism of the changes of the cryoglobulinemia and 
of the serum aminotransferases during recombinant 
interferon alfa administration suggest that HCV in- 
fection is responsible for the production of cryoglobu- 
linemia and vasculitis. It is proposed that HCV in- 
fection is a cause of cryoglobulinemia associated with 
chronic hepatitis. 
Agnello V., Chung R.T., Kaplan L.M. A role for 
hepatitis C virus infection in type I1 cryoglobulinemia. 
N Engl J Med 1992;327:1490-1495 
ABSTRACT 
Background. Type I1 cryoglobulinemia is a vasculitis 
characterized by cryoglobulins consisting of com- 
plexes of polyclonal IgG and monoclonal IgM rheu- 
matoid factors. The cause of these immune complexes 
is unknown, though both the hepatitis B (HBV) and C 
(HCV) viruses have been suspected. 
Methods. We studied 19 patients with Type I1 cryo- 
globulinemia for markers of HCV and HBV infection. 
Quantitative HCV antibody and RNA studies were 
performed on whole serum, cryoprecipitates, and su- 
pernatants. 
Results. Eight patients (42 percent) had HCV anti- 
bodies, and 16 (84 percent) had HCV RNA. Of the 19 
patients, 6 (26 percent) had HBV markers, but only 1 
had evidence of active HBV infection. Control serum 
samples from nine patients with Type I cryoglobu- 
linemia were negative for HCV antibody and HCV RNA. 
There was a close, although not exclusive, association 
of one type of rheumatoid factor (WA) with HCV RNA. 
HCV antibody and HCV RNA were concentrated ap- 
proximately 10-fold and 1000-fold, respectively, in the 
Type I1 cryoglobulins examined. 
Conclusions. Type I1 cryoglobulinemia is strongly 
associated with concomitant HCV infection and a high 
rate of false negative serologic tests. HCV virions and 
HCV antigen-antibody complexes are concentrated in 
the cryoprecipitates, most commonly in association 
with the WA type of rheumatoid factor, suggesting a 
